# Atrial Fibrillation Patient Preference Study

> **NCT02611635** · — · COMPLETED · sponsor: **Bayer** · enrollment: 382 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** VKA: Warfarin (Waran)
- **DRUG:** NOAC: Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** NOAC: Dabigatran etexilate
- **DRUG:** NOAC: Apixaban
- **DRUG:** NOAC: Edoxaban
- **DRUG:** NOAC: Lixiana

## Key facts

- **NCT ID:** NCT02611635
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-02
- **Primary completion:** 2017-01-26
- **Final completion:** 2017-02-16
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2018-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611635, "Atrial Fibrillation Patient Preference Study". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02611635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*